26 / 34
Schöffski P et al.
Oncol Res Treat
2014;37:355-62
© 2017 Eli Lilly and Company
As demonstrated in nonclinical studies, LARTRUVO binds PDGFR-α, preventing receptor activation.
LARTRUVO exhibited
in vitro
and
in vivo
anti-tumor activity against selected sarcoma cell lines and
disrupted the PDGFR-α signaling pathway in
in vivo
tumor implant models.
PDGFR-α is expressed on
cells of mesenchymal origin.
Signaling through this receptor
plays a role in cell growth,
chemotaxis, and mesenchymal
stem cell differentiation.
LARTRUVO is a PDGFR-α–
blocking antibody that specifically
binds PDGFR-α and prevents
receptor activation.
The receptor has also been
detected on some tumor and
stromal cells, including sarcomas,
where signaling can contribute
to cancer cell proliferation,
metastasis, and maintenance
of the tumor microenvironment.
LARTRUVO disrupted the
PDGFR-α signaling pathway in
in vivo
tumor implant models.
PDGFR-
α
SIGNALING
LARTRUVO DISRUPTS PDGFR-
α
SIGNALING
Olaratumab emergence in STS